Literature DB >> 17591849

In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.

Cédric Jacqueline1, Jocelyne Caillon, Virginie Le Mabecque, Anne-Françoise Miègeville, Antoine Hamel, Denis Bugnon, James Yigong Ge, Gilles Potel.   

Abstract

Using the rabbit endocarditis model, we compared the activity of a new broad-spectrum cephalosporin, ceftaroline, with those of linezolid and vancomycin against methicillin-resistant Staphylococcus aureus. After a 4-day treatment, ceftaroline exhibited superior bactericidal in vivo activity against resistant S. aureus strains and appeared to be the most effective drug against a heterogeneous glycopeptide-intermediate S. aureus strain.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17591849      PMCID： PMC2043200          DOI： 10.1128/AAC.01242-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Determination of linezolid in plasma by reversed-phase high-performance liquid chromatography.

Authors:  G W Peng; R P Stryd; S Murata; M Igarashi; K Chiba; H Aoyama; M Aoyama; T Zenki; N Ozawa
Journal:  J Pharm Biomed Anal       Date:  1999-06       Impact factor: 3.935

2.  Experimental bacterial endocarditis. II. Survival of a bacteria in endocardial vegetations.

Authors:  D T Durack; P B Beeson
Journal:  Br J Exp Pathol       Date:  1972-02

3.  Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.

Authors:  D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

4.  In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model.

Authors:  Cédric Jacqueline; Eric Batard; Lucia Perez; David Boutoille; Antoine Hamel; Jocelyne Caillon; Marie-France Kergueris; Gilles Potel; Denis Bugnon
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

5.  LB11058, a new cephalosporin with high penicillin-binding protein 2a affinity and activity in experimental endocarditis due to homogeneously methicillin-resistant Staphylococcus aureus.

Authors:  Jacques Vouillamoz; José M Entenza; Peter Hohl; Philippe Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

6.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

7.  In vivo antibacterial activity of S-3578, a new broad-spectrum cephalosporin: methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa experimental infection models.

Authors:  Masakatsu Tsuji; Morio Takema; Hideaki Miwa; Jingoro Shimada; Shogo Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

8.  RWJ-54428 (MC-02,479), a new cephalosporin with high affinity for penicillin-binding proteins, including PBP 2a, and stability to staphylococcal beta-lactamases.

Authors:  Francois Malouin; Johanne Blais; Suzanne Chamberland; Monica Hoang; Craig Park; Christin Chan; Kristina Mathias; Samia Hakem; Kelly Dupree; Eric Liu; Tien Nguyen; Michael N Dudley
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

9.  In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599.

Authors:  Yuji Iizawa; Junko Nagai; Tomoyasu Ishikawa; Shohei Hashiguchi; Masafumi Nakao; Akio Miyake; Kenji Okonogi
Journal:  J Infect Chemother       Date:  2004-06       Impact factor: 2.211

10.  Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart.

Authors:  B B Perlman; L R Freedman
Journal:  Yale J Biol Med       Date:  1971-10
View more
  33 in total

Review 1.  Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

Authors:  Thomas P Lodise; Donald E Low
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

2.  PBP2a mutations causing high-level Ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates.

Authors:  S Wesley Long; Randall J Olsen; Shrenik C Mehta; Timothy Palzkill; Patricia L Cernoch; Katherine K Perez; William L Musick; Adriana E Rosato; James M Musser
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

Review 3.  Molecular basis and phenotype of methicillin resistance in Staphylococcus aureus and insights into new beta-lactams that meet the challenge.

Authors:  Leticia I Llarrull; Jed F Fisher; Shahriar Mobashery
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

4.  In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing.

Authors:  Steven D Brown; Maria M Traczewski
Journal:  Antimicrob Agents Chemother       Date:  2008-12-29       Impact factor: 5.191

Review 5.  Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia.

Authors:  James E Frampton
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

6.  Ceftaroline versus ceftriaxone in a highly penicillin-resistant pneumococcal pneumonia rabbit model using simulated human dosing.

Authors:  Delphine Croisier-Bertin; Lionel Piroth; Pierre-Emmanuel Charles; Aurélie Larribeau; Donald Biek; Yigong Ge; Pascal Chavanet
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

7.  Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae.

Authors:  Megan K Luther; Marios Arvanitis; Eleftherios Mylonakis; Kerry L LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

8.  Ceftobiprole efficacy in vitro against Panton-Valentine leukocidin production and in vivo against community-associated methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits.

Authors:  Azzam Saleh-Mghir; Oana Dumitrescu; Aurélien Dinh; Yassine Boutrad; Laurent Massias; Emilie Martin; François Vandenesch; Jérôme Etienne; Gérard Lina; Anne Claude Crémieux
Journal:  Antimicrob Agents Chemother       Date:  2012-10-01       Impact factor: 5.191

9.  In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.

Authors:  Amira A Bhalodi; Mao Hagihara; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

Review 10.  Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus.

Authors:  George G Zhanel; Grace Sniezek; Frank Schweizer; Sheryl Zelenitsky; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2009       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.